- Home
- KPRX vs CXAI Comparison
KPRX vs CXAI Comparison
Compare KPRX & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | CXAI |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KPRX | CXAI |
|---|---|---|
| Price | $2.13 | $0.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 77.1K | ★ 8.2M |
| Earning Date | 03-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,222,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $0.21 |
| 52 Week High | $4.18 | $1.69 |
Technical Indicators
Market Signals| Indicator | KPRX | CXAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 32.13 |
| Support Level | $2.15 | $0.27 |
| Resistance Level | $2.45 | $0.34 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 25.58 | 3.23 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.